Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Urothelial cancers can grow in different parts of the urinary tract. This includes the ureter (the tube that carries urine from the kidneys to the bladder) and renal pelvis. The renal pelvis is where the ureter connects to the kidneys. The standard treatment is surgery to remove the ureter, kidney, or both. In this study, researchers want to see if enfortumab vedotin, given before surgery, is useful for treating urothelial cancers. The people in this study have high-risk urothelial cancers of the upper urinary tract. High risk means there is a greater chance of the cancer coming back after treatment.
Researchers want to see if Tec-RVd after 3 treatment cycles of Dara-RVd is safe for people with multiple myeloma. The people in this study have newly diagnosed multiple myeloma.
The standard approach to controlling pain after mastectomy includes intravenous and oral pain-relieving medications. In this study, researchers are determining if adding a long-acting local anesthetic, bupivacaine, into the wound at the end of the operation is more effective at reducing pain than the standard medications alone for women having a mastectomy on one side with no immediate reconstruction afterward.
KIF5B/RET is an abnormal gene that leads to the growth of lung cancer cells. Cabozantinib inhibits the effects of this gene. In addition, this drug interferes with other pathways that also cause cancer cells to grow, form new blood vessels, and spread to other parts of the body.
Researchers want to find the best doses of BNT323 and BNT327 to treat breast cancer. The people in this study have breast cancer that has spread and keeps growing after treatment.
Researchers are assessing a new combination therapy for neuroblastoma that has a high chance of coming back after treatment. This study is for children with high-risk neuroblastoma who have not gotten more than 1 chemotherapy cycle.
Researchers want to see if giving stereotactic radiosurgery (SRS) after osimertinib is better than osimertinib alone for advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that metastasized (spread) to the brain. Their cancers have a mutation (change) in the EGFR gene, and they are taking or planning to take osimertinib.
